New antifungal formulation gets FDA OK

July 23, 2007

Extina Foam, from Stiefel Laboratories, contains 2% ketoconazole and is approved by the FDA for the treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.

New antifungal formulation gets FDA OKKetoconazole will now be available in a new formulation. Extina Foam, from Stiefel Laboratories, contains 2% ketoconazole and is approved by the FDA for the treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older. The new product utilizes VersaFoam HF (hydroethanolic formulation) technology as its delivery vehicle, which allows for quick absorption. Extina should be applied twice daily to affected areas of the skin for four weeks.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.